Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists (Q44345528)

2 December 2017

title

Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists (English)

1 reference

2 December 2017

Alan D Adams

1

1 reference

2 December 2017

Winston Yuen

2

1 reference

2 December 2017

Zao Hu

3

1 reference

2 December 2017

Conrad Santini

4

1 reference

2 December 2017

A Brian Jones

5

1 reference

2 December 2017

Karen L MacNaul

6

1 reference

2 December 2017

Joel P Berger

7

1 reference

2 December 2017

Thomas W Doebber

8

1 reference

2 December 2017

David E Moller

9

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Bioorganic & Medicinal Chemistry Letters

2 December 2017

published in

1 reference

2 December 2017

volume

13

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

931-935

1 reference

The PPARs: from orphan receptors to drug discovery

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Micronized fenofibrate: a new fibric acid hypolipidemic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Troglitazone. Is it all over?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Troglitazone-associated hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Severe hepatotoxicity associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Phenoxy acid herbicides cause peroxisome proliferation in Chinese hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

On the attribution and additivity of binding energies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901029-6

7 January 2021

10.1016/S0960-894X(02)01029-6

Identifiers

DOI

1 reference

2 December 2017

1 reference